Close Menu

More articles about Business News

Finnzymes had $20 million in revenues in 2009 and makes reagents, consumables, kits, and instruments for molecular biology applications.

The alliance will combine Beckman Coulter Genomics' sequencing capabilities with Genpathway's ChIP sequencing data and analysis.

Galapagos expects its drug discovery services operations to bring in around €70 million in 2010 revenues.

The firm has raised nearly $80 million since its inception. Funds will be used to accelerate development of its sequencing technology.

Danaher has closed the acquisition, and the mass spec operations will operate under the name AB Sciex. MDS plans to return the majority of proceeds from the sale to shareholders through a share buyback.

The settlement will end a dispute dating back more than two years and likely help CombiMatrix as it continues to seek "strategic options" for the company.

BG has filed for an IPO in the US, a few years after withdrawing an effort to float on the Euronext Amsterdam Exchange.

The firm's instrument and reagents growth were strong for the fourth quarter, as the firm beat analysts' estimates.

Gamida has acquired the array technology that Elitech bought from Nanogen last year.

The firm's revenues rose nearly 12 percent, with growth coming largely from its diagnostics division.

The matter is of particular importance since UMass is the only one of the four organizations to which the IP is assigned to have licensed it to companies other than Alnylam.

According to the company, the miRNA is linked to a variety of diseases including cancer, fibrosis, and heart disease.

The patent describes the modulation of claudins, which are proteins associated with tumor progression and metastasis.

The company's common stock is now traded on the Over-The-Counter Bulletin Board.

Although the suit was first filed last summer, the courtroom showdown had been brewing for years.

The FTC provided provisional approval of Danaher's purchase of MDS Analytical Technologies. However, it is requiring MDS to sell its laser microdissection business to Life Technologies to alleviate the agency's competition concerns.

The joint venture in the Dallas area will offer clinical lab services, molecular diagnostics, and pharmacogenomic tests and will focus on cancer.

The agro-tech company will use Fluidigm's tools under a global agreement in its field and vegetable plant programs.

PerkinElmer withdrew the patent infringement suit only a week after filing it.

The firm has partnered with Cold Spring Biotech, Pharmatech, and Research Instruments.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.